Advertisement
News
Advertisement

Medco Research Institute® and AssureRx Health Initiate Pilot Program to Evaluate Adoption and Clinical Impact of Pharmacogenetic Testing for Selection of Psychotropic Medicat...

Wed, 05/11/2011 - 5:33am
Bio-Medicine.Org

FRANKLIN LAKES, N.J. and CINCINNATI, May 11, 2011 /PRNewswire/ -- Medco Research Institute LLC, a wholly owned subsidiary of Medco Health Solutions Inc. (NYSE: MHS), and AssureRx Health Inc. today announced the initiation of the PREDICT PSYMEDS pilot [Pharmacogenetic-Directed Prescribing of Psychotropic Medications] to evaluate antidepressant and antipsychotic drug adherence and medical care utilization by Medco members after being genotyped with AssureRx's GeneSightRx, a multi-gene pharmacogenetic profile test.

GeneSightRx measures and analyzes multiple clinically important genetic variants that can help physicians understand the way a patient's unique genetic makeup affects his or her ability to tolerate or effectively respond to certain psychotropic medications.  

"Genetic variations are important considerations for patients taking psychotropic medications, leading to differences in how patients tolerate and respond to antidepressants and antipsychotics," said Felix Frueh, Ph.D., president, Medco Research Institute. "The PREDICT PSYMEDS pilot is designed to demonstrate how pharmacogenetic-guided prescribing can add precision to these therapies. We hope that we can demonstrate that using such technology can help improve patient drug response and reduce side effects, and result in cost savings to payors."

Medco Research Institute will identify 2,000 Medco members for GeneSightRx testing who are currently taking one or more of 26 FDA-approved antidepressant and antipsychotic medications and who switched or added psychotropic medications within a prior three-month period.

Upon physician test requisition, GeneSightRx testing will involve participants' submission of a cheek swab to AssureRx's dedicate

'/>"/>

SOURCE

Topics

Advertisement

Share this Story

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading